Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chromid-like secondary replicons as predicted key sites of biosynthetic gene clusters in <i>Ktedonobacteria</i>.

mSystems·2026

Same author

Continuous administration of lenvatinib after first documented disease progression in patients with radioiodine-refractory thyroid cancer.

Endocrine·2026

Same author

Real-world platinum selection in immune checkpoint inhibitor-based therapy for recurrent or metastatic head and neck cancer: an exploratory multi-institutional retrospective study.

Scientific reports·2026

Same author

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Cancers·2026

Same author

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.

European thyroid journal·2026

Same author

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

Future oncology (London, England)·2026

Search research articles

Related Experiment Video

Updated: Feb 26, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

[Molecular Target Therapy for Soft Tissue Sarcoma].

Shunji Takahashi¹

¹Dept. of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|July 13, 2017

Summary

Soft tissue sarcomas (STS) are rare cancers often resistant to chemotherapy. Developing targeted therapies, like Trabectedin for translocation-related sarcomas, is crucial for improving patient outcomes.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Soft tissue sarcoma (STS) represents a group of rare and challenging malignancies.
Most STS subtypes exhibit resistance to conventional chemotherapy, necessitating novel therapeutic strategies.
Specific chromosomal translocations are observed in 20-30% of STS cases, yielding transcriptional factors that are difficult to target directly.

Purpose of the Study:

To review the current landscape of targeted therapies for soft tissue sarcomas.
To highlight the challenges and advancements in developing molecularly targeted treatments for STS.
To discuss the efficacy of existing and emerging therapeutic agents, including Trabectedin, angiogenesis inhibitors, and immune checkpoint inhibitors.

Main Methods:

Literature review of studies on soft tissue sarcoma treatment.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Related Experiment Videos

Last Updated: Feb 26, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Analysis of therapeutic strategies targeting chromosomal translocations and gene mutations in STS.

Evaluation of the role of angiogenesis inhibitors and immune checkpoint inhibitors in STS management.

Main Results:

Trabectedin demonstrates efficacy in translocation-related sarcomas (TRS) by alkylating DNA and inhibiting transcriptional factors.
Targeted therapies for gene mutations (e.g., c-kit, PDGFR) have shown success in specific rare sarcomas like GIST, IMT, and DFSP.
Angiogenesis inhibitors (e.g., pazopanib) and immune checkpoint inhibitors are emerging as potential treatments for STS.

Conclusions:

Development of specific molecular targeted therapies tailored to individual STS subtypes is essential.
Trabectedin offers a treatment option for translocation-related sarcomas.
Further research into angiogenesis inhibition and immunotherapy holds promise for advancing STS treatment.